

Additional file 2. Clinical usefulness of omalizumab in allergic asthma patients

Omalizumab in clinical studies in allergic asthma patients showed to be able:

- To decrease IgE-induced bronchoconstriction during both the early and late- phase responses to inhaled allergen during the bronchial provocation tests.
- To reduce allergic asthma exacerbations regardless of the type of allergic sensitisation.
- To have a corticosteroid sparing effect.
- To reduce the use of bronchodilators.
- To improve the nasal symptoms in subjects with allergic rhinitis associated with asthma.
- To improve symptoms of urticaria and atopic dermatitis.
- To improve quality of life in patients with asthma, also in those with severe persistent allergic asthma that is inadequately controlled by currently available asthma medication.